Filing Details
ImmunityBio, Inc. (NASDAQ:IBRX) filed a Form 8-K with the Securities and Exchange Commission on October 14, 2026, disclosing a material event.
8k filedNASDAQ:IBRX
ImmunityBio, Inc. (IBRX) Reports Material Event to SEC
ImmunityBio, Inc. (NASDAQ:IBRX) filed a Form 8-K with the Securities and Exchange Commission on October 14, 2026, disclosing a material event.
At publication ·
What changed
ImmunityBio, Inc. (NASDAQ:IBRX) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- ImmunityBio, Inc. filed a Form 8-K with the SEC on October 14, 2026, disclosing a material event requiring shareholder notification.
- The company's stock trades at $9.91 with a market capitalization of $2.2 billion as a healthcare company.
- Material events reported on Form 8-K filings can include leadership changes, acquisitions, asset sales, or financial guidance modifications.
Market Context
ImmunityBio, Inc.'s stock currently trades at $9.91 with a market capitalization of $2.2B. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for ImmunityBio, Inc.'s stock.
All SEC filings for ImmunityBio, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View IBRX Stock Page
Frequently Asked Questions
Where can I read IBRX's SEC filings?
Browse all filings on our IBRX SEC filings page.
What types of SEC filings does ImmunityBio, Inc. file?
Public companies like ImmunityBio, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.